Elsevier

Sexual Medicine Reviews

Volume 7, Issue 1, January 2019, Pages 84-94
Sexual Medicine Reviews

Review
Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications

https://doi.org/10.1016/j.sxmr.2018.09.006Get rights and content

Abstract

Introduction

Selective androgen receptor modulators (SARMs) differentially bind to androgen receptors depending on each SARM’s chemical structure. As a result, SARMs result in anabolic cellular activity while avoiding many of the side effects of currently available anabolic steroids. SARMs have been studied in the treatment of breast cancer and cachexia and have also been used as performance-enhancing agents. Here, we evaluate and summarize the current literature on SARMs.

Aim

To present the background, mechanisms, current and potential clinical applications, as well as risks and benefits of SARMs.

Methods

A literature review was performed in MEDLINE using the terms selective androgen receptor modulator, hypogonadism, cachexia, breast cancer, benign prostatic hyperplasia, libido, and lean muscle mass. Both basic research and clinical studies were included.

Main Outcome Measure

To complete a review of peer-reviewed literature.

Results

Although there are currently no U.S. Food and Drug Agency-approved indications for SARMs, investigators are exploring the potential uses for these compounds. Basic research has focused on the pharmacokinetics and pharmacodynamics of these agents, demonstrating good availability with a paucity of drug interactions. Early clinical studies have demonstrated potential uses for SARMs in the treatment of cancer-related cachexia, benign prostatic hyperplasia (BPH), hypogonadism, and breast cancer, with positive results.

Conclusion

SARMs have numerous possible clinical applications, with promise for the safe use in the treatment of cachexia, BPH, hypogonadism, breast cancer, and prostate cancer.

Solomon ZJ, Mirabal JR, Mazur DJ, et al. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sex Med Rev 2019;7:84–94.

Introduction

The androgen receptor (AR) belongs to the superfamily of steroid hormone nuclear receptors, and the binding of its endogenous ligands (ie, testosterone and dihydroxytestosterone [DHT]) modulates its function as a transcription factor.1 The effects of the interaction between the AR and androgens are complex and vary depending on sex, age, tissue type, and hormonal status. Although the AR is widely known for its role in male sexual development and maintenance, it also has important effects on bone density, strength, muscle mass, hematopoiesis, coagulation, metabolism, and cognition.2, 3

Testosterone and synthetic steroid hormones have found many applications in the clinical setting. One can broadly categorize their effects as anabolic (increased bone density, muscle mass) or androgenic (impaired fertility, virilization, acne). Despite the wide array of medical conditions that potentially could be addressed with the supplementation of steroid hormones, their therapeutic use is often curtailed owing to potential side effects, including erythrocytosis, prostate hypertrophy, hepatotoxicity, aromatization to estrogen, and testicular atrophy.4 The use of testosterone therapy in prostate cancer (PCa) is a topic of controversy and was debated in an article by Jannini et al.5 The authors conclude that PCa is indeed testosterone dependent. However, AR saturation in the prostate is thought to occur at subphysiologic serum testosterone levels (60–120 ng/dL). As such, increases in serum testosterone levels above this concentration are not expected to result in further AR activation and activity.6 There is no conclusive evidence demonstrating an increased risk of PCa in the setting of testosterone therapy. Of interest, Gravina et al7 demonstrated a significant reduction in the tumor growth of PCa cells in the setting of supraphysiologic intraprostatic testosterone concentrations.

Selective androgen receptor modulators (SARMs) are small-molecule drugs that can exert varying degrees of both agonist and antagonist effects on ARs in different tissues. Their actions can be understood by considering the selective estrogen receptor modulators (SERMs) that preceded them. One SERM widely used to treat breast cancer, tamoxifen, acts as an antagonist in the breast, an agonist in the bone, and a partial agonist in the uterus. The tissue-specific effects of these agents are precisely what makes them attractive, because they can be tailored to address specific medical conditions while minimizing off-target effects.

Basic laboratory experiments have sought to investigate and optimize the pharmacodynamic and pharmacokinetic properties of SARMs according to their desired site of action. SARMs have been chemically engineered to more specifically target AR function in certain tissues while minimizing off-target effects.8 There is minimal variation between AR structure, but the regulatory milieu of each tissue allows SARMs to possess relative tissue specificity. Animal models have been used to investigate the effect of SARMs on skeletal muscle in both eugonadal and hypogonadal rats.9 Animal models of muscular dystrophy have been used to investigate the use of SARMs in muscle pathology, demonstrating encouraging results.9, 10 SARMs have also been trialed as reversible hormonal contraceptives in rats.11 Although still preliminary studies, researchers have investigated the possible use of SARMs in Alzheimer’s disease, PCa, benign prostatic hyperplasia (BPH), and osteoporosis.12, 13, 14 SARMs have begun to be studied in the preclinical and clinical phases as treatment options for cancer-related cachexia, breast cancer, BPH, and hypogonadism.2, 15, 16 There are several ongoing Phase 1 and Phase 2 clinical trials investigating the use of SARMs.

In this review, we present the background, mechanisms, and current and future clinical applications of SARMs. We also consider the risks and benefits of SARMs and discuss their potential for misuse.

Section snippets

Methods

A literature review was performed in the PubMed/Medline database using the terms selective androgen receptor modulator, hypogonadism, cachexia, breast cancer, benign prostatic hyperplasia, and lean muscle mass. Both basic and clinical studies were included. Currently ongoing clinical trials listed on http://www.clinicaltrials.gov that are investigating SARMs were reviewed as well.

History of SARMS

An improved understanding of SERMs and their mechanisms of action in the 1990s, as well as the growing use of tamoxifen in the treatment of breast cancer, stimulated interest in analogous drugs to modulate the AR.17, 18 Several laboratories began working on identifying lead candidates and specific pharmacophores, with early work centered around a class of aryl-propionamides identified from hydroxyflutamide analogs in 1998.15 Over the past 20 years, the number of bioactive SARMs under

Biochemical and Basic Science Background

As demonstrated by the development and clinical use of SERMs such as tamoxifen, the key characteristic underlying the therapeutic potential of SARMs is their tissue specificity. While steroid hormone replacement therapy offers many benefits, it can be associated with a high rate of adverse effects (AEs), partly owing to widespread and non-specific activation of the AR in many different tissues. The most basic distinction in tissue selectivity lies between anabolic and androgenic effects of

Male Contraception

SARMs show promise for use as a method of male contraception in animals. Exogenous testosterone interferes with spermatogenesis via negative feedback on the hypothalamic–pituitary–gonadal (HPG) axis.11, 22 Chen et al11 demonstrated that administration of a SARM, C-6, markedly suppressed spermatogenesis and reduced peripheral testosterone levels while decreasing testicular and epididymal size. Similar experiments by Jones et al23 using a SARM, S-23, combined with estradiol benzoate, demonstrated

Conclusion

The AR is a complex signaling apparatus with important effects on tissue development, growth, and maintenance. Although steroid hormones have valuable clinical applications, their widespread activation of AR receptors gives rise to treatment-limiting side effects. Like the SERMs before them, SARMs and their tissue selectivity demonstrate the potential to revolutionize the treatment of many debilitating diseases. Depending on their chemical structure, SARMs can act as agonists, antagonists,

Statement of Authorship

Category 1

  1. (a)

    Conception and Design

    • Zachary Solomon, Jorge Rivera Mirabal, Daniel Mazur, Taylor Kohn, Alexander Pastuszak

  2. (b)

    Acquisition of Data

    • Zachary Solomon, Jorge Rivera Mirabal

  3. (c)

    Analysis and Interpretation of Data

    • Zachary Solomon, Jorge Rivera Mirabal, Daniel Mazur, Taylor Kohn, Larry Lipshultz, Alexander Pastuszak

Category 2
  1. (a)

    Drafting the Article

    • Zachary Solomon, Jorge Rivera Mirabal, Daniel Mazur, Taylor Kohn, Alexander Pastuszak

  2. (b)

    Revising It for Intellectual Content

    • Zachary Solomon, Jorge Rivera Mirabal, Alexander Pastuszak,

References (59)

  • F. Labrie et al.

    Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy

    J Sex Med

    (2015)
  • G. Ciocca et al.

    Is testosterone a food for the brain?

    Sex Med Rev

    (2016)
  • A.S. Dobs et al.

    Effects of enobosarm on muscle wasting and physical function in patients with cancer: A double-blind, randomised controlled phase 2 trial

    Lancet Oncol

    (2013)
  • I. Bhattacharya et al.

    Safety, pharmacokinetic, and pharmacodynamic evaluation after single and multiple ascending doses of a novel selective androgen receptor modulator in healthy subjects

    Clin Ther

    (2016)
  • C.P. Miller et al.

    Design, synthesis, and preclinical characterization of the selective androgen receptor modulator (SARM) RAD140

    ACS Med Chem Lett

    (2011)
  • J. Crawford et al.

    Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER Trials)

    Curr Oncol Rep

    (2016)
  • J.T. Dalton et al.

    The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: Results of a double-blind, placebo-controlled phase II trial

    J Cachexia Sarcopenia Muscle

    (2011)
  • R. Unwalla et al.

    Structure-based approach to identify 5-[4-hydroxyphenyl]pyrrole-2-carbonitrile derivatives as potent and tissue selective androgen receptor modulators

    J Med Chem

    (2017)
  • N. Olea et al.

    The proliferative effect of “anti-androgens” on the androgen-sensitive human prostate tumor cell line lncap

    Endocrinology

    (1990)
  • G.L. Gravina et al.

    Episode-like pulse testosterone supplementation induces tumor senescence and growth arrest down-modulating androgen receptor through modulation of p-ERK1/2, pARser81 and CDK1 signaling: biological implications for men treated with testosterone replacement therapy

    Oncotarget

    (2017)
  • A.L. Handlon et al.

    Optimizing ligand efficiency of selective androgen receptor modulators (SARMs)

    ACS Med Chem Lett

    (2016)
  • S. Ponnusamy et al.

    Androgen receptor agonists increase lean mass, improve cardiopulmonary functions and extend survival in preclinical models of Duchenne muscular dystrophy

    Hum Mol Genet

    (2017)
  • J. Chen et al.

    A selective androgen receptor modulator for hormonal male contraception

    J Pharmacol Exp Ther

    (2005)
  • M.F. Zilbermint

    Nonsteroidal selective androgen receptor modulator OstarineTM in cancer cachexia

    Futur Oncol

    (2009)
  • H. Nejishima et al.

    Anti-androgenic effects of S-40542, a novel non-steroidal selective androgen receptor modulator (SARM) for the treatment of benign prostatic hyperplasia

    Prostate

    (2012)
  • V.C. Jordan

    Selective estrogen receptor modulation

    Cancer Res

    (2001)
  • J. Chen

    Discovery and therapeutic promise of selective androgen receptor modulators

    Mol Interv

    (2005)
  • A. Saeed et al.

    2-Chloro-4-[[(1R,2R)-2-hydroxy-2-methyl-cyclopentyl]amino]-3-methyl-benzonitrile: A transdermal selective androgen receptor modulator (SARM) for muscle atrophy

    J Med Chem

    (2016)
  • T.P. Kohn et al.

    Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapy

    Fertil Steril

    (2017)
  • Cited by (0)

    Conflicts of Interest: The authors report no conflicts of interest.

    Funding: A.W.P. is a National Institutes of Health K08 Scholar supported by a Mentored Career Development Award (K08DK115835-01) from the National Institute of Diabetes and Digestive and Kidney Diseases. This work is also supported in part through a Urology Care Foundation Rising Stars in Urology Award (to A.W.P.).

    View full text